MX2022016243A - Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca. - Google Patents
Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca.Info
- Publication number
- MX2022016243A MX2022016243A MX2022016243A MX2022016243A MX2022016243A MX 2022016243 A MX2022016243 A MX 2022016243A MX 2022016243 A MX2022016243 A MX 2022016243A MX 2022016243 A MX2022016243 A MX 2022016243A MX 2022016243 A MX2022016243 A MX 2022016243A
- Authority
- MX
- Mexico
- Prior art keywords
- actrii
- alk4
- antagonists
- heart failure
- methods
- Prior art date
Links
- 206010019280 Heart failures Diseases 0.000 title abstract 5
- 239000005557 antagonist Substances 0.000 title abstract 4
- 208000031229 Cardiomyopathies Diseases 0.000 abstract 1
- 206010028289 Muscle atrophy Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 201000000585 muscular atrophy Diseases 0.000 abstract 1
- 201000006938 muscular dystrophy Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/401—Proline; Derivatives thereof, e.g. captopril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/495—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
En algunos aspectos, la divulgación se refiere a antagonistas de ActRII-ALK4 y a métodos para usar antagonistas de ActRII-ALK4 para tratar, prevenir o reducir la tasa de evolución y/o la gravedad de la insuficiencia cardíaca (HF), en particular para tratar, prevenir o reducir la tasa de evolución y/o la gravedad de una o más comorbilidades asociadas con HF. La divulgación también proporciona métodos para usar un antagonista de ActRII-ALK4 para tratar, prevenir o reducir la tasa de evolución y/o la gravedad de la insuficiencia cardíaca asociada con una variedad de afecciones que incluyen, entre otras, cardiomiopatías genéticas, enfermedades de emaciación muscular y distrofias musculares.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202063040400P | 2020-06-17 | 2020-06-17 | |
US202163159003P | 2021-03-10 | 2021-03-10 | |
PCT/US2021/037557 WO2021257655A1 (en) | 2020-06-17 | 2021-06-16 | Actrii-alk4 antagonists and methods of treating heart failure |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2022016243A true MX2022016243A (es) | 2023-03-08 |
Family
ID=79268368
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022016243A MX2022016243A (es) | 2020-06-17 | 2021-06-16 | Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca. |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP4168036A1 (es) |
JP (1) | JP2023534127A (es) |
KR (1) | KR20230025432A (es) |
CN (1) | CN116113440A (es) |
AU (1) | AU2021293908A1 (es) |
BR (1) | BR112022025473A2 (es) |
CA (1) | CA3182523A1 (es) |
MX (1) | MX2022016243A (es) |
WO (1) | WO2021257655A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2024511315A (ja) * | 2021-03-10 | 2024-03-13 | アクセルロン ファーマ インコーポレイテッド | Actrii-alk4アンタゴニスト及び心不全の治療方法 |
KR20230169124A (ko) * | 2021-03-10 | 2023-12-15 | 악셀레론 파마 인코포레이티드 | Actrii-alk4 길항제 및 심부전을 치료하는 방법 |
JP2023059858A (ja) * | 2021-10-15 | 2023-04-27 | リサーチ インスティチュート アット ネイションワイド チルドレンズ ホスピタル | 自己相補的アデノ随伴ウイルスベクター及び筋ジストロフィーの治療におけるその使用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA41919A (fr) * | 2015-04-06 | 2018-02-13 | Acceleron Pharma Inc | Hétéromultimères alk4:actriib et leurs utilisations |
RS62011B1 (sr) * | 2016-07-15 | 2021-07-30 | Acceleron Pharma Inc | Kompozicije koje sadrže polipeptide actriia za upotrebu u lečenju plućne hipertenzije |
WO2018067879A1 (en) * | 2016-10-05 | 2018-04-12 | Acceleron Pharma Inc. | Alk4:actriib heteromultimers and uses thereof |
-
2021
- 2021-06-16 WO PCT/US2021/037557 patent/WO2021257655A1/en unknown
- 2021-06-16 BR BR112022025473A patent/BR112022025473A2/pt unknown
- 2021-06-16 AU AU2021293908A patent/AU2021293908A1/en active Pending
- 2021-06-16 CN CN202180056305.2A patent/CN116113440A/zh active Pending
- 2021-06-16 KR KR1020237000845A patent/KR20230025432A/ko unknown
- 2021-06-16 JP JP2022577551A patent/JP2023534127A/ja active Pending
- 2021-06-16 MX MX2022016243A patent/MX2022016243A/es unknown
- 2021-06-16 EP EP21826739.1A patent/EP4168036A1/en active Pending
- 2021-06-16 CA CA3182523A patent/CA3182523A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
KR20230025432A (ko) | 2023-02-21 |
WO2021257655A1 (en) | 2021-12-23 |
AU2021293908A1 (en) | 2023-01-19 |
BR112022025473A2 (pt) | 2023-03-07 |
JP2023534127A (ja) | 2023-08-08 |
CN116113440A (zh) | 2023-05-12 |
EP4168036A1 (en) | 2023-04-26 |
CA3182523A1 (en) | 2021-12-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022016243A (es) | Antagonistas de actrii-alk4 y métodos para el tratamiento contra insuficiencia cardíaca. | |
MX2018001435A (es) | Metodos de tratamiento del sindrome de lennox-gastaut con fenfluramina. | |
MX2019013279A (es) | Metodos de tratamiento del sindrome de doose utilizando fenfluramina. | |
EA201100393A1 (ru) | Применение усиливающих агентов, возможно связанных с рибофлавином, а также соответствующих офтальмологических композиций для перекрестного сшивания роговицы при лечении кератоконуса или других эктазийных расстройств роговицы | |
UA85055C2 (ru) | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний | |
MX2021004708A (es) | Metodos y composiciones para tratamiento de presbicia, midriasis y otros trastornos oculares. | |
MX2018003179A (es) | Terapia de combinación con cenicriviroc para el tratamiento de fibrosis. | |
MX2010003548A (es) | Metodos para el tratamiento de padecimientos neurologicos autoinmunes con ciclofosfamida. | |
MY197558A (en) | Methods of treating depression using orexin-2 receptor antagonists | |
NZ752918A (en) | Treatment of prostate cancer | |
WO2014144606A3 (en) | Methods of treating muscular dystrophy | |
WO2020047352A8 (en) | Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack | |
MX2022009736A (es) | Compuestos y metodos de p2x3 y/o p2x2/3. | |
MX2023000187A (es) | Dosificacion de vibegron para el tratamiento de vejiga sobreactiva. | |
MX2022000845A (es) | Compuestos inhibidores. | |
JOP20200253A1 (ar) | تركيبات وطرق لعلاج الحثل البقعي | |
MX2021013356A (es) | Tratamiento y prevencion de enfermedades metabolicas. | |
MX2016016295A (es) | Metodos para tratar enfermedades cardiovasculares. | |
MX2022010093A (es) | Tafoxiparina para el tratamiento de la preeclampsia. | |
MX2022005448A (es) | Método de tratamiento de queratodermia palmoplantar. | |
MX2021007490A (es) | Tratamiento de la hipercoagulopatia en el sindrome de cushing mediante la administracion de moduladores del receptor de glucocorticoides. | |
MX2021003825A (es) | Procedimientos de tratamiento de capas de grasa subcutanea. | |
MX2023004881A (es) | Inhibidores de pde9 para el tratamiento de insuficiencia cardíaca. | |
HK1072012A1 (en) | 5-ht4 receptor antagonists for the treatment of heart failure | |
EP4234022A3 (en) | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject |